Abstract | BACKGROUND: (90)Y ibritumomab tiuxetan is a radioimmunotherapeutic construct that is reported to be an effective treatment for patients with lymphoma. The aim of the current analysis was to evaluate retrospectively the efficacy and safety of (90)Y ibritumomab tiuxetan in patients with Richter syndrome (RS). METHODS: RESULTS: CONCLUSIONS: (90)Y ibritumomab tiuxetan had no significant antitumor activity and hematologic toxicity was severe in these heavily pretreated patients with RS.
|
Authors | Apostolia-Maria Tsimberidou, James L Murray, Susan O'Brien, William G Wierda, Michael J Keating |
Journal | Cancer
(Cancer)
Vol. 100
Issue 10
Pg. 2195-200
(May 15 2004)
ISSN: 0008-543X [Print] United States |
PMID | 15139064
(Publication Type: Journal Article, Multicenter Study)
|
Copyright | Copyright 2004 American Cancer Society. |
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- Yttrium Radioisotopes
- ibritumomab tiuxetan
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Bone Marrow
(pathology)
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
(complications, immunology, therapy)
- Lymphoma, B-Cell
(immunology, therapy)
- Male
- Middle Aged
- Radioimmunotherapy
- Retrospective Studies
- Syndrome
- Treatment Outcome
- Yttrium Radioisotopes
(therapeutic use)
|